Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and n...
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company d...
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for pa...
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for pa...
Kyverna is seeking a Commercial Corporate Counsel who will serve as a key legal partner to the commercial, medical af...
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
